School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
Research center of big data and meta-analysis, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan.
Int J Eat Disord. 2022 Jun;55(6):733-746. doi: 10.1002/eat.23714. Epub 2022 Apr 22.
This study was designed to determine the status of dehydroepiandrosterone (DHEA) in women with anorexia nervosa (AN) and to assess the efficacy of DHEA supplementation as a treatment for bone health in women with AN.
Studies were retrieved from the PubMed, Embase, Cochrane Library, MEDLINE, and Scopus databases from inception to February 14, 2022. Observational studies that compared serum DHEA levels between women with AN and healthy controls were included for meta-analysis, and randomized controlled trials (RCTs) that evaluated the effects of DHEA supplementation on bone mass were reviewed.
Meta-analysis of 15 cross-sectional studies revealed that patients with AN had significantly elevated serum DHEA levels (mean difference (MD) = 311.63 ng/dl; 95% confidence interval (CI), 78.01-545.25) and reduced DHEAS levels (MD = -24.90 μg/dl; 95% CI, -41.72 to -8.07) compared with healthy controls. A systematic review of seven RCTs found that DHEA monotherapy does not improve bone mineral density (BMD) compared with placebo after adjusting for weight gain. While the combination of DHEA and conjugated oral contraceptives has led to increased bone strength and decreased bone loss, the beneficial effect appears to be limited to older adolescents and adults with closed physes. Potential detrimental effects on BMD were identified in younger adolescents with open physes in one study.
Due to the lack of apparent benefit of DHEA in women with AN and its potential detrimental effect on BMD in young patients with AN, current evidence does not support the use of DHEA.
This study demonstrates that women with anorexia nervosa have abnormal levels of dehydroepiandrosterone (DHEA) and dehydroepiandrosterone sulfate (DHEAS), which have been suggested by previous studies to play a role in the development of low bone density in this condition. However, current evidence does not support the use of DHEA as a treatment to preserve bone health in patients with anorexia nervosa given the lack of clear benefit following its use and also because of a potential detrimental effect on bone mineral density in young patients with anorexia nervosa.
本研究旨在确定厌食症(AN)女性脱氢表雄酮(DHEA)的状况,并评估 DHEA 补充剂作为治疗 AN 女性骨骼健康的疗效。
从 1980 年 1 月至 2022 年 2 月 14 日,从 PubMed、Embase、Cochrane 图书馆、MEDLINE 和 Scopus 数据库中检索研究。纳入比较 AN 女性和健康对照者血清 DHEA 水平的观察性研究进行荟萃分析,并综述了评估 DHEA 补充剂对骨量影响的随机对照试验(RCT)。
15 项横断面研究的荟萃分析显示,与健康对照组相比,AN 患者血清 DHEA 水平显著升高(均数差(MD)=311.63ng/dl;95%置信区间(CI),78.01-545.25),DHEAS 水平降低(MD=-24.90μg/dl;95%CI,-41.72 至-8.07)。对 7 项 RCT 的系统评价发现,与安慰剂相比,DHEA 单药治疗并不能增加体重增加后的骨密度(BMD)。尽管 DHEA 与口服结合避孕药联合使用可增加骨强度和减少骨丢失,但这种有益作用似乎仅限于已闭合骺板的青少年和成年人。一项研究发现,在骺板尚未闭合的年轻 AN 患者中,DHEA 可能对 BMD 有不利影响。
由于 DHEA 对 AN 女性的益处不明显,且对 AN 年轻患者的 BMD 有潜在的不利影响,目前的证据不支持使用 DHEA。
本研究表明,厌食症女性存在脱氢表雄酮(DHEA)和脱氢表雄酮硫酸盐(DHEAS)水平异常,这与之前的研究表明 DHEA 可能在这种情况下的低骨密度发展中发挥作用一致。然而,鉴于目前使用 DHEA 后缺乏明确的益处,且其对年轻 AN 患者的骨密度可能有潜在的不利影响,目前的证据不支持将 DHEA 作为治疗厌食症患者骨骼健康的方法。